A Prospective Field Study: Introducing the Shang Ring in Routine Clinical Settings

September 26, 2012 updated by: FHI 360

A Prospective Study of Male Circumcision Using the Shang Ring in Routine Clinical Settings in Kenya & Zambia

Male Circumcision (MC) is the only new biomedical method to demonstrate consistent efficacy as an HIV prevention intervention in randomized controlled trials (WHO and UNAIDS, 2007), based on three randomized controlled trials in Kenya, Uganda, and South Africa, that reported a protective effect of about 60%

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The World Health Organization, the Joint United Nations Programme on HIV/AIDS (UNAIDS), and other global reproductive health organizations have recognized the highly protective effect of male circumcision to prevent HIV infection in men. Male Circumcision (MC) is the only new biomedical method to demonstrate consistent efficacy as an HIV prevention intervention in randomized controlled trials, based on three randomized controlled trials in Kenya, Uganda, and South Africa, that reported a protective effect of about 60%. Subsequent studies have confirmed the value and persistence of MC's protection against HIV infection, and have demonstrated that MC also reduces the transmission of human papillomavirus.

A wide variety of instruments, devices, and techniques are used around the world for male circumcision. The WHO, UNAIDS and JHPIEGO document entitled Manual for Male Circumcision under Local Anesthesia, includes step-by-step instructions for performing adult male circumcision using three different surgical procedures: the forceps-guided, dorsal slit, and sleeve resection methods. Procedure times for these techniques are approximately 20-30 minutes excluding anesthesia and involve control of unavoidable bleeding and a significant amount of suturing, and can be associated with complications that include hematoma formation, infection, unsatisfactory cosmetic result, lacerations of the penile or scrotal skin and injury to the glans, particularly among inexperienced surgeons. Although training is necessary regardless of method, devices for MC have the potential to reduce both training time and surgical duration because neither hemostasis nor suturing is needed for most devices.

The Shang Ring is an innovative device for adult male circumcision that has been on the Chinese market since 2005. The Shang Ring is manufactured by Wuhu SNNDA Medical Treatment Appliance Technology Co., Ltd (SNNDA).

In the current African setting, only surgical circumcision is available for adults. Devices such as the Shang Ring have the potential to simplify and shorten surgery by eliminating the need for suturing and hemostasis. Data from two small studies in Kenya suggest that the Shang Ring has an acceptable safety profile. A randomized controlled trial was conducted in Kenya and Zambia to provide further data.

Circumcision using the Shang Ring involves a few simple steps. First, a special measuring strip is used to determine which Shang Ring size to use. Following administration of local anesthesia, the inner ring is fitted at the base of the glans penis. Next, the foreskin is everted over the inner ring and the outer ring is secured (locked) over the inner ring, thus encasing the foreskin. The sterile device forms a tight seal. The foreskin is excised and several nicks are made in the foreskin on the underside of the device to prevent formation of a stiff, circumferential scab. Bleeding is minimal and no suturing or hemostasis is required. Finally, the participant returns in seven days for removal of the Shang Ring device. After removal, a bandage is applied to the wound. Men may be given a supply of bandages and told to change the bandaging daily or as needed.

Study Type

Interventional

Enrollment (Actual)

1200

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Nyanza
      • Homa Bay, Nyanza, Kenya, 40300
        • Homa Bay District Hospital male circumcision clinic
      • Lusaka, Zambia
        • Society for Family Planning Clinic

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 54 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

All men enrolled in this research study must meet the following inclusion criteria:

  • Must be aged 18 and 54 years;
  • Must be uncircumcised (on examination);
  • Must be in good general health;
  • Must agree to HIV counseling and testing no more than one week before the procedure;
  • Must be free of genital ulcerations or other visible signs of STI (on examination);
  • Must be able to understand study procedures and requirements of study participation;
  • Must agree to return to the healthcare facility for the full schedule of follow-up visits after his circumcision;
  • Must freely consent to participate in the study and sign a written informed consent form;
  • Must have a cell phone or access to a cell phone; and,
  • Must agree to provide the study staff with an address, phone number, or other locator information while participating in the research study.

Exclusion Criteria:

  • A man will be excluded from participation in this research study if he has any of the following exclusion criteria:

    • Has a known allergy or sensitivity to lidocaine or other local anesthesia;
    • Takes a medication that would be a contraindication for elective surgery, such as an anticoagulant or steroid;
    • Has known bleeding/clotting disorder (e.g. hemophilia); or
    • Has an active genital infection, anatomic abnormality or other condition (e.g. severe obesity, diabetes or sickle cell anemia), which in the opinion of the surgeon, prevents the man from undergoing a circumcision as part of this study;
    • Is currently participating in another biomedical study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: 42 days
42 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Acceptability of the Shang Ring Procedure
Time Frame: 42 days
42 days
Percentage of men completely healed at 42 days
Time Frame: 42 Days
42 Days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Marc Goldstein, M.D., Weill Cornell Medical College, NY, USA
  • Study Chair: Mark A Barone, DVM, MS, EngenderHealth, NY, USA
  • Principal Investigator: Philip S Li, MD, Weill Cornell Medical College, NY, USA
  • Principal Investigator: Richard Lee, MD, Weill Cornell Medical College, NY, USA
  • Principal Investigator: Paul Perchal, MA, EngenderHealth, NY, USA
  • Principal Investigator: Jared Mogouche, MD ChB, EngenderHealth, Kisumu, Kenya
  • Principal Investigator: Quentin Awori, MB ChB, EngenderHealth, Homa Bay, Kenya
  • Principal Investigator: Raymond Simba, MB ChB MPH, Homa Bay District Hospital, Ministry of Health, Homa Bay, Kenya
  • Principal Investigator: Nicholas Muraguri, MB ChB MPH, National AIDS/STD Control Programme, Nairobi, Kenya
  • Principal Investigator: John M Wekesa, MB ChB MMed, Ministry of Medical Services, Nairobi, Kenya
  • Principal Investigator: Kasonde Bowa, MSc M. Med FRCS FACS FCS, University of Zambia
  • Principal Investigator: Robert Zulu, MD, University Teaching Hospital, Lusaka, Zambia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2012

Primary Completion (Actual)

July 1, 2012

Study Completion (Actual)

August 1, 2012

Study Registration Dates

First Submitted

February 28, 2012

First Submitted That Met QC Criteria

March 28, 2012

First Posted (Estimate)

March 30, 2012

Study Record Updates

Last Update Posted (Estimate)

September 27, 2012

Last Update Submitted That Met QC Criteria

September 26, 2012

Last Verified

September 1, 2012

More Information

Terms related to this study

Other Study ID Numbers

  • 10728

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Male Circumcision

Clinical Trials on Shang Ring

3
Subscribe